Organigram-Hyasynth BiologicalsIn the short term, youre likely going to see many LPs taking advantage of GWs news, when in reality it will have little, if any, impact on most of them, unless they have deep expertise in R&D, plant genetics and clinical trials, David Kideckel, an analyst for Alberta-based ATB Capital Markets, told Marijuana Business Daily. There will be much upside, however, for specific companies playing in GWs wheelhouse. Kideckel highlighted New Brunswick-based Organigram and its partnership with biosynthetic player Hyasynth Biologicals, Ontario-based Cardiol Therapeutics and Alberta-headquartered Willow Biosciences as three examples of the kind of companies that might draw some interest. https://mjbizdaily.com/gw-pharmaceuticals-sale-might-spur-pharma-cannabis-deal-making/amp/t.